Open AccessPlacenta derived Mesenchymal Stem Cells transplantation in Type 1 diabetes: preliminary report of phase 1 clinical trial
Author(s) -
Sedigheh Madani,
Aria Setudeh,
Hamid Reza Aghayan,
Sepideh Alavi-Moghadam,
Mahtab Rouhifard,
Negar Rezaei,
Parastoo Rostami,
Reihaneh Mohsenipour,
Davoud Amirkashani,
Fatemeh Bandarian,
Babak Arjmand,
Bagher Larijani
Publication year - 2021
Publication title -
journal of diabetes and metabolic disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.619
H-Index - 33
ISSN - 2251-6581
DOI - 10.1007/s40200-021-00837-9
Subject(s) - medicine , transplantation , type 1 diabetes , clinical trial , glycemic , adverse effect , diabetes mellitus , randomized controlled trial , mesenchymal stem cell , surgery , insulin , endocrinology , pathology
Type 1 Diabetes Mellitus (T1DM) is an auto immune reaction against insulin secreting beta cells. Exogenous insulin administration is the only standard treatment for T1DM. However, despite tight glycemic control many patients will develop chronic life-threatening complications. Recently, stem cell transplantation has been suggested as a novel treatment for eliminating the beta cell damage and promoting their regeneration by modulating auto-immunity. To our knowledge; this is the first preliminary report of placenta derived MSCs (PLMSCs) transplantation in juvenile T1DM.